Hjem › Spiserørkreft › New York › New York City
Kliniske studier for Spiserørkreft i New York City, NY
22 studier for Spiserørkreft søker deltakere på steder i og rundt New York City (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RekruttererFase 1
- NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
- NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
- Icahn School of Medicine at Mount Sinai, New York
- og 2 flere
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RekruttererFase 2
- Memorial Sloan Kettering Hospital, New York
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
RekruttererFase 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
RekruttererFase 1
- New York University (NYU) Langone Medical Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RekruttererFase 1
- New York University (NYU) Clinical Cancer Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RekruttererFase 1/2
- Columbia University, New York
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RekruttererFase 1
- Memorial Sloan Kettering Cancer Center Head Neck Services, New York
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
RekruttererFase 3
- Icahn School of Medicine at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma
RekruttererFase 1/2
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RekruttererFase 1
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
RekruttererFase 3
- Research Site, New York
- Research Site, New York
- Research Site, New York
Retrospective Review of Esophageal Cancer at MSKCC
RekruttererObservasjonsstudie
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
RekruttererFase 1
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
- Columbia University Medical Center, New York
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
RekruttererFase 1/2
- Mt. Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
RekruttererFase 2
- Memorial Sloan Kettering Cancer Center, New York
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RekruttererFase 1
- North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists, New York
- Columbia University Irving Medical Center, New York
Registry for Esophageal and Gastroesophageal Junction Cancer
RekruttererObservasjonsstudie
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Brodalumab in the Treatment of Immune-Related Adverse Events
RekruttererFase 1
- Columbia University Irving Medical Center, New York
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
RekruttererFase 1/2
- Weill Cornell Medicine, Cornell University (site 126), New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruttererObservasjonsstudie
- Massive Bio SYNERGY-AI site, New York
Spiserørkreft-studier i andre byer
- Houston, TX36 studier
- Boston, MA23 studier
- Nashville, TN19 studier
- St. Louis, MO17 studier
- Pittsburgh, PA15 studier
- Los Angeles, CA15 studier
- Baldwin Park, CA14 studier
- Grand Rapids, MI14 studier
- Philadelphia, PA13 studier
- San Antonio, TX12 studier
- Rochester, MN11 studier
- Arlington, VA11 studier
Andre studier i New York City
- Brystkreft136 studier
- Ikke-småcellet lungekreft121 studier
- Kreft (alle typer)109 studier
- Prostatakreft103 studier
- Metastatisk kreft93 studier
- Kolorektal kreft78 studier
- Eggstokkreft69 studier
- Lungekreft60 studier
- Multipelt myelom60 studier
- Pankreaskreft60 studier
- Endometriekreft52 studier
- Akut myelogen leukemi51 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.